Trial Profile
A Study to Evaluate the Efficacy and Safety of Irinotecan plus Bevacizumab Combination in Patients with Heavily Treated Advanced Non Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Dec 2015
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Irinotecan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Dec 2015 New trial record